Recent News

• 06.10.2025 - CervoMed Announces New Hire to Support Neflamapimod Development and Commercialization
• 06.10.2025 - CervoMed Announces New Hire to Support Neflamapimod Development and Commercialization
• 05.12.2025 - CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates
• 05.12.2025 - CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates
• 05.07.2025 - CervoMed to Participate in H.C. Wainwright 3rd Annual BioConnect Investor Conference
• 05.07.2025 - CervoMed to Participate in H.C. Wainwright 3rd Annual BioConnect Investor Conference
• 04.04.2025 - Erika Example Event

Recent Filings

• 05.23.2025 - 3 Initial statement of beneficial ownership of securities
• 05.19.2025 - 8-K Current report
• 05.14.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.12.2025 - EX-99.1 EX-99.1
• 05.12.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 05.12.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.12.2025 - 8-K Current report
• 05.07.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 04.30.2025 - ARS Annual Report to Security Holders
• 04.29.2025 - DEF 14A Other definitive proxy statements